Wang, Zhijie <br/><br/>
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.  [electronic resource] 

 -  The Lancet. Respiratory medicine  09 2018 
 - 681-690 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2213-2619 
<br/><br/><label>Standard No.: </label>10.1016/S2213-2600(18)30264-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Administration, Oral<br/>Adult<br/>Aged<br/>Biomarkers, Tumor--blood<br/>Circulating Tumor DNA--blood<br/>DNA Mutational Analysis--methods<br/>Disease-Free Survival<br/>Female<br/>Gefitinib--administration & dosage<br/>Genes, Tumor Suppressor<br/>Genes, erbB-1<br/>Humans<br/>Intention to Treat Analysis<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Protein Kinase Inhibitors--administration & dosage<br/>Sensitivity and Specificity